Orchid Pharma (NSE:ORCHPHARMA, BOM:524372) received seven observations from the US Food and Drug Administration (US FDA) after a surprise inspection at its active pharmaceutical ingredient manufacturing facility at Alathur in Tamil Nadu, India, according to a Wednesday filing to the Indian stock exchanges.
The inspection was conducted from Feb. 10 to Feb. 18, which the company said "resulted in seven minor observations, none of which pertain to the data integrity of the facility."
The Alathur facility specializes in producing Cephalosporin antibiotics, a critical class of life-saving drugs.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.